Routine pharmacovigilance is not always enough to keep an important risk under control. When it is not, additional risk minimisation measures come into play, and since August 2024 the EU guidance on selecting and evaluating them, GVP Module XVI Revision 3, has asked more of marketing authorisation holders than its predecessor.
Routine versus additional measures
Routine measures, such as the summary of product characteristics, the package leaflet, pack size and legal status, apply to every medicine. Additional measures are reserved for important risks where routine measures are judged insufficient. They are agreed with the competent authorities, described in the risk management plan, and in the centralised procedure may become conditions of the marketing authorisation.
What Revision 3 changes
The EMA published the final guidance on 5 August 2024, together with a new Addendum II on methods for evaluating effectiveness. As we read it, the main shifts are:
- Messages and tools are separated. A measure is now framed as the message to be conveyed plus the tool that carries it, which pushes sponsors to justify why a given tool suits a given risk.
- Tool categories are clearer. Educational and safety advice tools (guides, checklists, patient cards) are distinguished from risk minimisation control tools, which replace the older language of controlled access and controlled distribution programmes.
- Effectiveness evaluation is more demanding. Methods now sit in Addendum II, and the guidance puts more weight on planning the evaluation early and on involving patient and healthcare professional representatives.
Revision 3 is most relevant for new applications, newly developed measures and new effectiveness studies. Existing programmes are not automatically reopened, but any amendment is a sensible moment to review them against the new text.
Where companies run into difficulty
- Choosing a heavier tool than the risk justifies, adding burden for prescribers without a safety gain.
- Leaving the effectiveness plan until after launch, when baseline data can no longer be collected.
- Treating national implementation as an afterthought: key elements are agreed at EU level, but the content, format and distribution of materials are agreed with each national authority, including the EOF in Greece.
- Relying on spontaneous reports to show that a measure works, which the guidance regards as unreliable for that purpose.
How PQRA helps
PQRA supports pharmaceutical companies with risk management plans, the design of educational materials and risk minimisation tools, effectiveness evaluation planning, and national implementation and authority liaison in Greece. We can also review existing programmes against Revision 3 and prepare them for inspection.
Planning a risk minimisation programme or reviewing an existing one? Contact PQRA for a practical discussion.


No responses yet